A pharmacy that registers as an outsourcing facility under Section 503B of the Federal Food, Drug, and Cosmetic Act does not merely add a federal registration on top of its existing compounding operation. Registration subjects the entire facility to the manufacturer-grade current good manufacturing practice requirements in 21 CFR Parts 210 and 211, a standard most compounding pharmacists were trained under USP <795>, USP <797>, and USP <800>, rather than under Part 211. That gap generates the Form FDA 483 observations, warning letters, and product recalls documented in FDA's enforcement record for outsourcing facilities.
Full CGMP Applies Under 21 CFR Parts 210 and 211
Section 501(a)(2)(B) of the FD&C Act requires outsourcing facilities to comply with current good manufacturing practice, and FDA's CGMP regulations for drug products sit in 21 CFR Parts 210 and 211. FDA has told outsourcing facilities, including in a March 2026 warning letter, that it applies Parts 210 and 211 until it finalizes CGMP regulations written specifically for outsourcing facilities, a rulemaking still in draft form. A pharmacy compounding under Section 503A for a patient-specific prescription is exempt from that framework and instead follows the USP <795>, USP <797>, and USP <800> compounding standards its state board of pharmacy has adopted. Health Law Alliance's comparison of the two frameworks covers where that statutory line falls.
Where 503B Requirements Exceed USP Compounding Standards
FDA's expectations under Part 211 go beyond what USP <795> and USP <797> require of a compounding pharmacy in several specific respects. 21 CFR 211.42(c)(10)(iv) requires an outsourcing facility to maintain a system for monitoring environmental conditions in its aseptic processing area on an ongoing basis. 21 CFR 211.113(b) requires written procedures preventing microbiological contamination, including validation of the aseptic process itself. 21 CFR 211.84(d)(1) and (d)(2) require an identity test on each shipment of every component lot, rather than a supplier's certificate of analysis alone. 21 CFR 211.188 requires complete batch production and control records for every batch, a burden most 503A pharmacies never carry. FDA's draft guidance also expects the facility to support any beyond-use date with formulation-specific stability data rather than the default beyond-use date categories a 503A pharmacy may rely on under USP <797>.
The Most-Cited Form FDA 483 Observation Categories
A review of FDA's Form FDA 483 data presented at the FDA Compounding Quality Center of Excellence's 2024 conference found production and process control deficiencies, including unvalidated aseptic processes and inconsistent monitoring, in close to 29 percent of all observations issued to outsourcing facilities. Facility control system failures, cleanroom design and air pressure differentials chief among them, ranked second at roughly 13 percent, and environmental and personnel monitoring gaps accounted for about 11 percent. Packaging and labeling defects made up roughly 9 percent. Health Law Alliance's guide to the Form FDA 483 response deadline covers what a facility owes FDA once an observation is issued.
A March 2026 Warning Letter Shows the Pattern
FDA's March 20, 2026, warning letter to RC Outsourcing, LLC, an Ohio outsourcing facility, illustrates the pattern. An August 2025 inspection led FDA to cite the firm under 21 CFR 211.192 for failing to extend a sterility failure investigation, traced to an operator's skin condition, to other batches from the same period. FDA also cited inadequate environmental monitoring under 21 CFR 211.42(c)(10)(iv), unvalidated aseptic processes under 21 CFR 211.113(b), deficient laboratory controls under 21 CFR 211.160(b), and incomplete batch records under 21 CFR 211.188. The facility recalled four lots of bevacizumab for lack of sterility assurance, and FDA found several corrective actions undocumented months after the Form FDA 483 issued.
A corrective action FDA cannot verify with documentation is a corrective action FDA will not credit.
Why Early Legal Counsel Is Critical
It is critical that compounding pharmacies operating as outsourcing facilities retain experienced healthcare defense counsel as soon as FDA issues a Form FDA 483, not after a warning letter follows. Early legal intervention shapes the written response FDA expects within 15 working days, keeps a corrective action plan from reading as an admission FDA can use against the facility, and keeps the documentation behind each action complete enough for FDA to credit. Delaying counsel until FDA rejects a facility's response narrows the options available when the Form FDA 483 was first issued.
How Health Law Alliance Can Help
Health Law Alliance represents compounding pharmacies and outsourcing facilities through FDA inspections, Form FDA 483 responses, and warning letter negotiations, as part of the firm's compounding pharmacy defense practice. If your facility has received a Form FDA 483 or a warning letter citing 21 CFR Part 211, or if you are evaluating whether 503B registration fits your pharmacy, contact us for a free, confidential consultation.
